Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This study is to assess the safety, tolerability, and pharmacokinetics (PK) of multiple
infusions of GS-5745 in adults with rheumatoid arthritis (RA). Participants will be
randomized in a 4:1 ratio to receive 1 intravenous (IV) infusion of GS-5745 or placebo every
2 weeks, for a total of 3 IV infusions.